Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aussie Biotech CSL Buys U.S. Firm Talecris With Help Of $1.55 Billion Share Sell-Off

This article was originally published in PharmAsia News

Executive Summary

CSL acquired North Carolina-based Talecris Biotherapeutics in a $3.1 billion deal. To raise funds for the purchase - the largest deal by an Australian healthcare company - CSL sold 47.5 million shares at a 5.8 percent discount to the last traded price for a total of $1.55 billion. CSL Managing Director Brian McNamee said the acquisition will help boost sales by more than a third with the addition of immune disorder treatments, including products for lupus and multiple sclerosis. Talecris reported about $1.12 billion of net debt as of March 2008. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts